Driving impressive growth for Eli Lilly and Co., nine-month sales of diabetes and obesity assets Mounjaro and Zepbound (both tirzepatide) are up by 89% and 56%, respectively, over last year, bringing ...

Biopharma financings across all categories totaled $29.96 billion in the third quarter (Q3) of 2026, down 14% from $34.8 ...

Australia’s strength in radiopharmaceutical research is running into a patient-access barrier that could undermine investment in trials, manufacturing and future therapies, industry executives warned ...

A proposed U.S. outbound investment rule could make direct investment and newco formation out of China “somewhere between hard and impossible” in its current form, RA Capital Management’s Joshua ...

A single cell RNA sequencing atlas of colorectal cancers (CRC) from patients ages 29 to 90-plus, has pinpointed age-associated differences in tumor composition and gene expression, creating a ...

Financing, IPOs and M&As are three of the biggest drivers of momentum in the med-tech market, and right now the IPO window is largely closed, the volume of financing is down and M&A activity has ...

Wall Street reacted with satisfaction to Genmab A/S phase III data proving that doctors can gain oomph against cancer by ...

The U.S. FDA released briefing documents ahead of the Dermatologic and Ophthalmic Drugs Advisory Committee meeting scheduled ...

A perhaps unexpected theme of the first day of the European Society for Cell and Gene Therapy’s 2026 annual congress is how ...

Boston Scientific Corp. revised its guidance downwards for 2026, again, as it continues to have a challenging year. In ...

The endocannabinoid system is a neuromodulatory network that plays a crucial role in brain development and neuronal signaling ...

Mycobacterium tuberculosis remains a leading cause of infectious disease-mediated death, with 10.8 million reported cases of ...